Diagnostic Performance of the Pluslife MiniDock MTB and Molbio MTB Ultima Assays to Detect Tuberculosis From Tongue and Sputum Swabs Among Outpatients and in Active Case Finding in Cameroon
Authors:
- Cyrille MbuliCyrille Mbuli
- Jean Bosco Taya-FokouJTJean Bosco Taya-Fokou
- Rita NsamenangRNRita Nsamenang
- Nestor BiatuNBNestor Biatu
- Gildas NguimfackGNGildas Nguimfack
- Ngha Ndze MbuhNgha Ndze Mbuh
- Joceline KonsoJKJoceline Konso
- Zourriyah Adamou ManaZMZourriyah Adamou Mana
- Arthur Rausmis Nankouo-NjouonangANArthur Rausmis Nankouo-Njouonang
- Magdalene TiamuhMTMagdalene Tiamuh
- Norah Nyah NdiNNNorah Nyah Ndi
Open Access
- 23 December 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , e370-e378
Abstract
Background: Cost and infrastructure requirements limit access to current rapid molecular diagnostic testing for tuberculosis (TB). Recent developments in novel, swab-based assays that can be used closer to the point of care offer the potential to change the TB diagnostic landscape. Methods: We assessed the diagnostic accuracy of 2 tests, Molbio Truenat MTB Ultima (MTB Ultima) and Pluslife MiniDock MTB Test (MiniDock MTB), among consecutively enrolled individuals aged 15 years and older, against the reference standard of culture and comparators of microscopy and Xpert MTB/RIF Ultra. Two tongue swabs, either self-collected or healthcare worker collected, and 2 sputum specimens were requested from each participant; MiniDock MTB was tested the same day and MTB Ultima was tested after storage. Results: From February to June 2025, 1097 participants were enrolled in communities (382) and at health facilities (715). Sensitivities of sputum and tongue swabs on MiniDock MTB among 132 people with culture-positive TB were 86% (95% confidence interval [CI], 79–91) and 76% (95% CI, 68–82), respectively, and 67% (95% CI, 51–79) and 44% (29–59) among those with smear-negative TB. Sensitivities of sputum and tongue swabs on MTB Ultima were 84% (97/116; 95% CI, 76–89) and 74% (67/91; 95% CI, 64–82), respectively, and 58% (95% CI, 41–74) and 33% (95% CI, 18–53) among those with smear-negative TB. Conclusions: In this population, the performance of both MiniDock MTB and MTB Ultima on tongue and sputum swabs was similar to target product profile thresholds for near point-of-care TB tests. Further studies to evaluate performance in diverse populations and settings are needed.Keywords
Funding Information
- Global Affairs Canada (CA-3-D000920001)
This publication has 27 references indexed in Scilit:
- Diagnostic accuracy of swab-based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country evaluationEBioMedicine, 2025
- Comparison of the diagnostic accuracy of the Pluslife Mini Dock RHAM technology with Abbott ID Now and Cepheid GenXpert: A retrospective evaluation studyScientific Reports, 2024
- Trade-offs between clinical performance and test accessibility in tuberculosis diagnosis: a multi-country modelling approach for target product profile developmentThe Lancet Global Health, 2024
- New Manual Quantitative Polymerase Chain Reaction Assay Validated on Tongue Swabs Collected and Processed in Uganda Shows Sensitivity That Rivals Sputum-based Molecular Tuberculosis DiagnosticsClinical Infectious Diseases, 2024
- Implementation of large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosis: a retrospective evaluationScientific Reports, 2023
- Results from a roving, active case finding initiative to improve tuberculosis detection among older people in rural cambodia using the Xpert MTB/RIF assay and chest X-rayJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2018
- Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy studyThe Lancet Infectious Diseases, 2018
- Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 CountriesThe Journal of Infectious Diseases, 2017
- Rapid Molecular Detection of Tuberculosis and Rifampin ResistanceNew England Journal of Medicine, 2010
- Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2006